The companies ORION Pharma and AMOMED Pharma provide information about their sales cooperation which has existed since October 2018. The agreement entails the co-promotion throughout Germany of Empressin^® (Argipressin) and Rapibloc^® (Landiolol), two innovative compounds in the area of intensive and emergency medicine.

ORION Pharma is a proven, well networked specialist in the area of intensive medicine, with many years of expertise. With the successful introduction of SIMDAX^® (Levosimendan) and dexdor^® (Dexmedetomidine), ORION Pharma established itself as a competent specialist, and has been a reliable partner for cardiologists, cardiac surgeons, anaesthesiologists and intensive care medics in clinics in Germany, Austria and Switzerland. “The cooperation with AMOMED Pharma underscores our claim that, as a leading specialist in critical care, we decisively improve the treatment of intensive care patients”, said Dr. Robert Borgdorf, managing director of ORION Pharma.

AMOMED Pharma is an international, privately run pharmaceutical company headquartered in Vienna, with a high development potential. “The goal is clear: to ensure our position as a leading expert partner in intensive care and emergency medicine in the European market. When every second counts and the life of the patient is directly threatened, AMOMED Pharma delivers what specialists in emergency care need most: medicine at the decisive moment. With ORION Pharma, AMOMED has found a renowned partner for these two urgently needed drugs. We expect this cooperation to lead to a more rapid and increased use of Empressin^® and Rapibloc^® to the benefit of this critically ill patient group”, said Dr. Günther Kneissl-Mayer CEO of AMOMED Pharma.